How is pharmacogenetics changing clinical trial design for percutaneous coronary intervention?

Indeed, tailoring antiplatelet treatment regimens to an individual patient to optimize their safety and efficacy has represented a field of extensive investigation over the past decade [[6]]. Bedside testing of CYP2C19 vs. conventional clopidogrel treatment to guide antiplatelet therapy in ST-segment elevation myocardial infarction patients. Keywords: Pharmacogenetics; percutaneous coronary intervention; clinical trial; antiplatelet therapy; P2Y12 inhibitors EN Pharmacogenetics percutaneous coronary intervention clinical trial antiplatelet therapy P2Y12 inhibitors 383 385 3 05/23/23 20230501 NES 230501 1. In patients undergoing PCI, oral P2Y SB 12 sb inhibitors are generally used in addition to aspirin therapy, a regimen known as dual antiplatelet therapy (DAPT) [[1]]. [Extracted from the article]